Skip to Main Content

The Food and Drug Administration’s power to make important regulatory decisions is in question after a Supreme Court decision on Friday weakening federal agencies’ ability to interpret ambiguous statutory measures. The ruling could mean headaches not just for the teams of lawyers and scientists at the FDA, but for the drug and device companies the agency is charged with regulating.

While the Supreme Court’s decision is not expected to have major implications on the FDA’s bread-and-butter task — approving individual drugs and devices — it could open up many of the agency’s regulatory efforts to legal challenge, leading to the one thing industry hates more than a bad policy: uncertainty.

advertisement

“This decision is potentially going to have a destabilizing effect on the industry,” said Stacy Cline Amin, a former FDA chief counsel who now serves as a partner at Morrison Foerster. “They won’t have the same predictability of the regulatory system that they have now.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.